NCT04204850 2025-12-03
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
University Health Network, Toronto
Phase 2 Recruiting
Clinical Trials
4 trialsNCT06156410 2025-11-14
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
Children's Hospital of Philadelphia
Phase 1 Recruiting
NCT03634540 2024-12-20
MK-6482-003
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Active not recruiting
NCT01866293 2017-08-30
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed